RxDoctor Payments Data

Annike Don-Levy, APRN

Nurse Practitioner · Miami, FLNPI 1093226300

Payments from drug & device makers

$1,533in general payments, 2019–2025

Across 59 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$329
  • Procept Biorobotics Corporation$177
  • Endo Pharmaceuticals Inc.$177
  • Axonics, Inc.$135
  • Urovant Sciences Inc$131
  • Exact Sciences$87
  • plus $498 from 12 others

What the payments were for

  • Food & beverage$1,46896%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,533 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$1,229
Medicare patients
14
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron87$44,476
GemtesaVibegron50$33,687
Trospium Chloride25$1,786
Tamsulosin Hcl155$1,270
Methenamine Hippurate12$749
Tadalafil27$511
Estradiol11$469
Finasteride34$333
Alfuzosin Hcl ErAlfuzosin Hcl12$232
Ciprofloxacin Hcl31$171
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim43$126
Sildenafil Citrate13$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$81$44,47687 claims
Sumitomo Pharma America, Inc.Gemtesa$329$33,68750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →